ArticleClinical nuclear medicine2026
Refining M1-Stage Stratification in De Novo Metastatic Nasopharyngeal Carcinoma Using 18F-FDG PET/CT: Preliminary Evidence.
Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survival and patterns of recurrence in patients with nasopharyngeal carcinoma from a non-endemic region-A German multicenter analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo validate the American Joint Committee on Cancer (AJCC) 9th edition M1-stage subdivision for de novo metastatic nasopharyngeal carcinoma (DM-NPC) and explore preliminary evidence for a refined classification using 18F-FDG positron emission tomography/computed tomography (PET/CT)-derived metastatic burden. PATIENTS AND
methodsA retrospective cohort of 185 DM-NPC patients diagnosed between 2000 and 2022, who underwent pretreatment 18F-FDG PET/CT, was analyzed. Recursive partitioning analysis (RPA) identified prognostic cutoffs for metastatic lesions. Survival outcomes were compared between AJCC 9th edition M1 subgroups (M1a: ≤3 lesions; M1b: >3 lesions) and a redefined PET-based classification (Rd-M1a: single-organ, ≤4 lesions; Rd-M1b: >5 lesions or multiorgan).
resultsPatients with single-organ metastases and ≤4 lesions showed potentially superior overall survival (OS) (2-y OS: 60.4% vs. 29.0%; 3-y OS: 46.2% vs. 19.6%; P<0.001). Higher metastatic burden (>5 lesions) was independently associated with worse OS (HR: 1.81; 95% CI: 1.24-2.64; P=0.002). The redefined classification suggested better prognostic discrimination than the AJCC 9th edition (C-index: 0.594 vs. 0.562; AUC at 36 mo: 0.649 vs. 0.598). Patients classified as Rd-M1b had a significantly unfavorable OS compared with those in the Rd-M1a group (HR: 2.02, 95% CI: 1.39-2.92; P=0.002).
conclusionsThese preliminary findings suggest that 18F-FDG PET/CT may enhance M1-stage stratification by quantifying metastatic burden and distribution in patients with DM-NPC, potentially offering improved prognostic accuracy. However, as a single-institution retrospective study, external validation is essential to confirm these observations and guide personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.